Welcome to our dedicated page for Adagene SEC filings (Ticker: ADAG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adagene Inc.'s SEC filings document its foreign-private-issuer reporting for a clinical-stage biotechnology company developing antibody-based cancer immunotherapies. Form 6-K reports furnish clinical-data releases for muzastotug, regulatory updates for MSS colorectal cancer development, full-year financial results, business updates and notices of scientific presentations.
The filings also cover capital-structure and financing matters, including ADS offerings, underwriting agreements and the ADS-to-ordinary-share relationship. Other disclosures include licensing and collaboration agreements using SAFEbody technology, share-based compensation and equity accounts, governance updates, clinical development risks and exhibits furnished under Exchange Act reporting rules.
General Atlantic-affiliated funds report that they no longer beneficially own any Adagene Inc. shares. As of December 31, 2025, the group reports beneficial ownership of 0 American Depositary Shares (ADSs) and 0 underlying ordinary shares, equal to 0% of the class.
The filing notes that each ADS represents one and one quarter ordinary shares. Percentage calculations reference 58,914,087 ordinary shares outstanding as of June 30, 2025, as reflected in an Adagene prospectus filed with the SEC on January 9, 2026.
Adagene Inc. shareholder Vincent C. Smith and related entities filed an amended Schedule 13G reporting significant ownership of the company’s Ordinary Shares. Mr. Smith may be deemed to beneficially own 5,095,351 Ordinary Shares, or 8.7% of the class, including shares held directly and through affiliated entities.
The Vincent C. Smith, Jr. 2025 Annuity Trust beneficially owns 3,608,019 Ordinary Shares, representing 6.1% of the class, while VCS Master Holdings GP holds 185,701 Ordinary Shares, or 1.0%. These percentages are based on 58,914,087 Ordinary Shares outstanding as of June 30, 2025. The filing states the securities were not acquired to change or influence control of Adagene.
Adagene Inc. filed a 6-K highlighting its cash position and development plans for 2026. The company reported unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, which it anticipates will fund operations until late 2027. This figure is preliminary, unaudited, subject to finalization, and is not a substitute for audited US GAAP financial statements.
Adagene’s lead program, muzastotug (ADG126), is a masked anti-CTLA-4 antibody (SAFEbody) with FDA Fast Track designation, being studied in Phase 1b/2 and Phase 2 trials in combination with anti-PD-1 therapy, particularly in microsatellite stable metastatic colorectal cancer. A data update from the ongoing Phase 1b/2 study of muzastotug plus pembrolizumab in third-line and later MSS colorectal cancer patients remains on track for Q1 2026. The company emphasizes its platform technologies (SAFEbody, NEObody, POWERbody) aimed at improving the safety and precision of antibody-based cancer immunotherapies.
Adagene Inc. submitted a Form 6-K to furnish a press release about a new licensing agreement with Third Arc Bio. The agreement covers development of two masked CD3 T cell engagers that will use Adagene’s SAFEbody® technology. Detailed commercial and financial terms are contained in the referenced press release, filed as Exhibit 99.1.
Adagene Inc. filed a Form F-3 resale registration covering up to 10,625,000 ordinary shares or 8,500,000 ADSs to be offered from time to time by a selling shareholder. The registered securities are issuable upon conversion of 1,062,500 Series A Non-Voting Redeemable Convertible Preferred Shares that were sold in a private placement.
Adagene is not selling any securities and will receive no proceeds from sales under this prospectus; the selling shareholder will receive all sale proceeds. Each ADS represents 1.25 ordinary shares, and the ADSs trade on Nasdaq as ADAG. Sales may occur in public or private transactions at market or negotiated prices.
The prospectus highlights PRC-related regulatory and operational risks, including potential impacts from cybersecurity and data rules, and notes the historical HFCAA context regarding PCAOB inspections. Counsel indicates this secondary offering is not subject to CSRC filing based on current guidance.
Adagene Inc. has furnished a Form 6-K as a foreign private issuer to provide its financial results for the six-month period ended June 30, 2025. The submission points readers to two key exhibits: a press release discussing the six-month 2025 financial results and corporate update, and unaudited interim condensed consolidated financial statements for the six months ended June 30, 2024 and 2025.
The company also states that this Form 6-K, including Exhibits 99.1 and 99.2, is incorporated by reference into its existing registration statements on Form F-3 and Form S-8, so these updated results and disclosures are now legally part of those offering documents unless later superseded.